early low fat diet enriched with linolenic acid reduces liver … · 2016. 3. 28. · early low fat...
Post on 07-Nov-2020
1 Views
Preview:
TRANSCRIPT
EARLY LOW FAT DIET ENRICHED WITH LINOLENIC ACID REDUCES
LIVER ENDOCANNABINOID TONE AND IMPROVES LATE GLYCEMIC
CONTROL AFTER A HIGH FAT DIET CHALLENGE IN MICE
Laurent Demizieux, Fabiana Piscitelli#, Stephanie Troy-Fioramonti, Fabio Arturo Iannotti#,
Simona Borrino#, Joseph Gresti, Tania Muller, Jerome Bellenger†, Cristoforo Silvestri#,
Vincenzo Di Marzo# and Pascal Degrace
Running title : Early dietary n-3 fatty acids and endocannabinoid tone
Author’s affiliations :
Laurent Demizieux, Stephanie Troy-Fioramonti, Joseph Gresti, Tania Muller and Pascal
Degrace, Université de Bourgogne Franche-Comté, INSERM LNC UMR866, Team
Pathophysiology of Dyslipidemia, Faculty of Sciences Gabriel, 6 Bd Gabriel, F-21000 Dijon,
France
#Fabiana Piscitelli, Simona Borrino, Fabio Arturo Iannotti, Cristoforo Silvestri and Vincenzo
Di Marzo, Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio
Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy
†Jerome Bellenger, Team Lipid transfer proteins and lipoprotein metabolism INSERM U866 -
Université de Bourgogne Franche-Comté, Faculty of Sciences Gabriel, 6 Bd Gabriel, 21000,
Dijon, France
Page 1 of 41 Diabetes
Diabetes Publish Ahead of Print, published online April 5, 2016
Correspondence to :
Pascal Degrace, Université de Bourgogne Franche-Comté, INSERM LNC UMR866, Team
Pathophysiology of Dyslipidemia, Faculty of Sciences Gabriel, 6 Bd Gabriel, F-21000 Dijon,
France
Phone : +33380393736 ; Fax : +33380396330 ; e-mail : pascal.degrace@u-bourgogne.fr
Or
Vincenzo Di Marzo, Endocannabinoid Research Group, Institute of Biomolecular Chemistry,
Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.
Phone : +390818675093 (Office) ; Fax.: +39-081-8041770 ; e-mail : vdimarzo@icb.cnr.it
Word count : 5053 Number of tables : 2 Number of figures : 6
Page 2 of 41Diabetes
ABSTRACT
Evidence suggests that alterations of glucose and lipid homeostasis induced by obesity are
associated with elevation of endocannabinoid tone. The biosynthesis of the two main
endocannabinoids, N-arachidonoyl-ethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG),
which derive from arachidonic acid, is influenced by dietary fatty acids (FA).
We investigated whether exposure to n-3 FA at a young age may decrease tissue
endocannabinoid levels and prevent metabolic disorders induced by a later high-fat diet
(HFD) challenge. Three week-old mice received a 5% lipid diet containing either lard or lard
+ safflower oil or lard + linseed oil for 10 weeks. Then, mice were challenged with a 30%
lard diet for 10 additional weeks.
A low n-6/n-3 FA ratio in the early diet induces a marked decrease in liver endocannabinoid
levels. A similar reduction was observed in transgenic Fat-1 mice which exhibit high tissue
levels of n-3 FA compared to wild type mice. Hepatic expression of key enzymes involved in
carbohydrate and lipid metabolism was concomitantly changed. Interestingly, some gene
modifications persisted after HFD challenge and were associated with improved glycemic
control.
These findings indicate that early dietary interventions based on n-3 FA may represent an
alternative strategy to drugs to reduce endocannabinoid tone and improve metabolic
parameters in the metabolic syndrome.
Page 3 of 41 Diabetes
INTRODUCTION
The endocannabinoid system (ECS) is known to play a crucial role in energy
homeostasis. Regulation by this system takes place at the central level by changing food
intake (1) and at the peripheral level by modification of energy metabolism (2). An overactive
ECS plays a crucial role in obesity by increasing food intake (3) and lipogenesis (4), by
down-regulating catabolic reactions (5; 6); and promoting fat accumulation and alteration of
glucose homeostasis. As a consequence, treating obesity by decreasing ECS activity has been
considered. A pharmacological approach was developed, leading to the commercialization of
an inverse agonist of the cannabinoid receptor type-1 (CB1R), Rimonabant. However, this
drug was withdrawn from the market due to its undesired central nervous system side effects
(7). Meanwhile, down-regulation of ECS tone in peripheral tissues involved in energy
homeostasis, either with non-brain penetrant CB1R blockers, or inhibitors of the biosynthesis
of endogenous CB1R agonists, is still considered as a potential approach to counter the
adverse events observed in obesity (8).
The ECS is defined as a set of endogenous ligands (endocannabinoids; EC),
synthesized and degraded by specific enzymes and receptors able to bind these molecules. It
includes two membrane receptors, CB1R and CB2R, and two main endogenous agonists, N-
arachidonoyl-ethanolamine (anandamide or AEA) and 2-arachidonoyl-glycerol (2-AG). AEA
is typically synthesized by the enzyme N-acylphosphatidylethanolamine phospholipase D
(NAPE-PLD), although alternative pathways exist, while 2-AG is formed by the action of
diacylglycerol lipase α or β upon diacylglycerols. After release, EC are subjected to rapid
breakdown by degrading enzymes such as fatty acid amide hydrolase (FAAH) for N-
acylethanolamines and monoacylglycerol lipase (MAGL) for 2-AG (9) (Figure 1A).
Page 4 of 41Diabetes
AEA and 2-AG are lipids and both ultimately derive from arachidonic acid (AA,
C20:4n-6) via AA-containing phospholipids. AA is endogenously biosynthesized from the
essential fatty acid (10) linoleic acid (LA, C18:2n-6). As a consequence, a dietary
supplementation in LA (11; 12) or AA itself (13) is able to elevate tissue contents of EC.
Conversely, diets enriched with n-3 polyunsaturated fatty acids (PUFA), such as
eicosapentaenoic acid (EPA; C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3), cause a
decrease in 2-AG and AEA levels because of the replacement of AA in phospholipids with
such FA (13; 14).
It is well known that dietary n-3 FA exert beneficial effects on obesity (15). For
instance, n-3 FA have the ability to reduce ectopic fat and inflammation in Zucker rats and to
reduce glucose intolerance generally associated with obesity (16). Thus, they were shown to
improve insulin sensitivity and gluconeogenesis in rodents (17,18). The existence of a direct
causal link between EC tone and the ability of n-3 FA to improve some of these features of
obesity has been recently evidenced (16), involving transcription factors such as CREBH (19)
and SREBP (20). This emphasizes the potential benefits of nutritional interventions in the
treatment of pathologies related to obesity, particularly using n-3 FA.
Accumulating evidence shows that dietary factors, including lipids, in developmental
periods such as fetal life, infancy, and early childhood, are associated with obesity risk later in
life (21). In line with this, it has been shown that early overnutrition leads to persistent
dysregulation in leptin and insulin sensitivity (22), along with enhanced inflammatory
response (23). In addition to excess calories, the FA composition of the perinatal diet is also
an important factor in the nutritional programming of the metabolic phenotype in adulthood.
Recent studies have shown that perinatal exposure to a rich n-6 FA diet is able to induce
obesity and to affect body fat mass across generations (24). On the other hand, the beneficial
role of dietary n-3 FA during early life has been emphasized since n-3 FA deficiency
Page 5 of 41 Diabetes
increases adiposity in guinea pigs (25). This idea was reinforced by the study of Masseria et
al. showing that addition of α-linolenic acid (α-LNA, C18:3n-3) to a LA rich high-fat diet
(HFD) under isolipidic and isocaloric conditions, reduces the deleterious effect of n-6 FA
when given to mouse pups (26). The beneficial preventive effect of n-3 FA is not restricted to
HFD. Even in a normolipidic diet, they are able to limit HFD-induced insulin resistance and
hepatic steatosis, two main features of obesity (27). In keeping with this, improvement of
glucose and lipid homeostasis was also observed in transgenic Fat-1 mice, which can
synthesize n-3 FA from n-6 FA without the need for dietary supplementation (28).
In this study, we aimed to investigate the role of the FA composition of a normolipidic
diet (n-6 vs n-3 FA) in the early prevention of HFD-induced obesity and its relationship with
the EC tone. Our starting hypothesis was that a n-3 FA enriched diet given to weaning mice
can decrease ECS activity, which in turn prevents HFD-induced metabolic disorders. To
support our data, we also examined liver EC tone in Fat-1 mice presenting consistently high
levels of n-3 FA in their tissues.
RESEARCH DESIGN AND METHODS
Animals and diets
Official French regulations (n°87848) for the use and care of laboratory animals were
followed throughout the experimental period. The experimental protocol was approved by the
local ethic committee for animal experimentation (n°BX0622). Three week-old C57BL/6J
male mice were purchased from Charles River Laboratories (France). Mice surviving to the
stress of delivery were randomly separated in 3 series of 14-16 animals receiving different
low fat diets (LFD; 5% wt/wt total lipids) for 10 weeks as schematized in Figure 1B. Animals
were housed individually on a 12h/12h light/dark schedule at 22–23°C with ad libitum access
Page 6 of 41Diabetes
to water and food. Lipids in Lard series came exclusively from pork fat while lard was
partially substituted with safflower oil or linseed oil in SAF and LIN series respectively. The
FA composition of the custom diets manufactured by SSNIF (Soest, Germany) is presented in
Table 1. After 10 weeks, half of the population of each series was used for analyses and the
rest was challenged with a high fat diet (HFD; 30% wt/wt total lipids from lard) for an
additional period of 10 weeks. C57BL/6J transgenic fat-1 mice were generated and housed as
described previously (29).
Body and plasma parameters
Body composition (fat mass, lean mass, and total body water) was measured by EchoMRI
(Echo Medical Systems; Houston, TX). Plasma triglyceride (TG) and cholesterol (CS)
concentrations were determined using commercial kits (Dyasis, France). Adiponectin levels
were measured by enzyme-linked immunosorbent assay (ELISA) from Merck Millipore
(Darmstadt, Germany) while leptin and insulin plasma content was determined using a
luminex®-based Bio-Rad® Bio-Plex Pro™ mouse assay (Bio-Rad, Marnes-La-Coquette
France).
Glucose tolerance and insulin tolerance tests
For oral glucose tolerance test (OGTT) and insulin tolerance test (ITT), mice respectively
received an oral load (2g/kg) of a D-glucose solution (20% w/v) or an intraperitoneal injection
of insulin (0.5 UI/kg; Actrapid®, Novo Nordisk, France) after a 6-hour fasting. OGTT and
ITT were performed on the same mice within a 3-day interval. Glycemia was measured at 0,
15, 30, 45, 60, 90, and 120 minutes directly in blood sampled from the tail vein with a My
Life PuraTM glucose meter (Ypsomed, Paris, France). During OGTT, larger blood samples (25
µl) were collected from tail in tubes containing EDTA (Sarstedt, Nümbrecht, Germany) to
Page 7 of 41 Diabetes
measure insulinemia at time 0, 15, 30 and 60 minutes after glucose load. Insulin levels were
determined using an Ultrasensitive mouse ELISA kit (Eurobio, Les Ulis, France).
Lipid and EC analyses
For determination of total FA composition in tissues and diets, lipids were extracted
according to Folch et al. (30). Concentrations were determined using C17:0 as internal
standard, after methylation according to the procedure of Christie (31) and separation by gas
chromatography (GC) as previously described (32). EC and congeners were purified from
lipid extracts and determined by isotope dilution liquid chromatography-atmospheric pressure
chemical ionization-mass spectrometry (LC-MS) using deuterated standards as described in
(33).
Western blots analysis
The isolation and quantification of total proteins from tissues was performed as previously
described (34). Briefly, from each animal previously anesthetized, the liver was isolated and
immediately frozen in liquid nitrogen. Each tissue was subsequently washed in cold PBS
(without Ca2+ and Mg2+, pH 7.4) and homogenized in a lysis solution containing: 150 mM
NaCl, 1 mM EDTA, 1% (v/v) TritonX-100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 20 mM Tris–HCl pH 8, 1% SDS, plus protease inhibitors)
at pH 7.4. Lysates were incubated 30 min at 4°C on a shaker and then centrifuged for 15 min
at 13,000 × g at 4◦C. Supernatants were transferred into clear tubes and quantified by DC
Protein Assay (Bio-Rad). Subsequently the samples (60–80 µg of total protein) were boiled
for 5 min in Laemmli SDS loading buffer and loaded on 8–10% SDS-polyacrylamide gel
electrophoresis and then transferred to a PVDF membrane. Filters were incubated overnight at
4◦C with the following antibodies: (a) mouse anti-FAAH clone 4H8 (dilution 1:1000; Sigma–
Page 8 of 41Diabetes
Aldrich); (b) rabbit anti-NAPE-PLD (dilution 1:2500; Abnova, Taiwan); (c) rabbit anti-
MAGL (dilution 1:200; Cayman Chemicals, Ann Arbor, MI, USA). The monoclonal anti-
tubulin clone B-5-1-2 (dilution 1:5000; Sigma–Aldrich) was used to check for equal protein
loading. Reactive bands were detected by chemiluminescence by the use of Clarity Western
ECL substrate (Bio-Rad). Images were analyzed on a Chemi-Doc station with Quantity-one
software (Bio-Rad).
Enzyme assays
FAAH and MAGL activity was measured as previously described (34). In particular, 2-AG
hydrolysis was measured by incubating the 10.000 x g liver cytosolic fraction (100
µg/sample) in Tris-HCl 50 mM, at pH 7.0 at 37 °C for 20 min, with synthetic 2-arachidonoyl-
[3H]-glycerol (40 Ci/mmol, ARC St. Louis, MO, USA) properly diluted with 2-AG (Cayman
Chemicals) to the final concentration of 10 µM. The amount of [3H]- glycerol produced was
measured by scintillation counting of the aqueous phase after extraction of the incubation
mixture with 2 volumes of CHCl3/CH3OH (1/1 ; v/v). AEA hydrolysis was measured by
incubating the 10,000 x g liver membrane fraction (70-100 µg/sample) in Tris-HCl l50 mM,
at pH 9-10 at 37°C for 30 min, with synthetic N-arachidonoyl-[14C]-ethanolamine (55
mCi/mmol, ARC St. Louis, MO, USA) properly diluted with AEA (Tocris Bioscience,
Avonmouth, Bristol, UK) to the final concentration of 2 µM. The amount of [14C]-
ethanolamine produced was measured by scintillation counting of the aqueous phase.
Activities were calculated in pmol of substrate hydrolyzed x min−1x mg protein−1.
RT-PCR
Total mRNAs from tissues were extracted with Tri-Reagent (Euromedex, Souffelweyersheim,
France) and 1 µg RNA was reverse-transcripted using the Iscript cDNA kit (Bio-Rad). Real-
Page 9 of 41 Diabetes
time PCR was performed as described previously (6) using a StepOnePlus™ real-time PCR
system (Life Technologies, Saint-Aubin, France). Primer sequences used for amplification are
indicated in Supplementary Table 1. For each gene, a standard curve was established from
four cDNA dilutions (1/10 to 1/10000) and used to determine the relative gene expression
variation after normalization with the geometric mean of 3 housekeeping genes (TATA box
binding protein, L38 and 18S).
Statistical analysis
Results are expressed as means ± SEM. Data were analyzed statistically using 2-way
ANOVA followed by the Tukey post-hoc test, or using Student t-test. Differences were
considered significant at P<0.05.
RESULTS
Liver total FA composition
Lard used for the preparation of the LFD was partially replaced by safflower oil (SAF)
or linseed oil (LIN) to modify the proportions of LA and α-LNA while limiting background
variations. In this way, the final n-6/n-3 FA ratios in Lard, SAF and LIN diets were 22, 53 and
1 respectively (Table 1). The impact of 10 weeks feeding with the different LFD was
estimated through the analysis of total liver FA composition (Table 1). As expected, when
compared to Lard, SAF diet increased proportions of LA and AA in liver lipids at the expense
of C18:1n-9, while LIN induced an increase in DHA. This resulted in strong alterations of
tissue n-6/n-3 FA ratios. After challenging the animals with a 30% lard oil diet for 10 weeks,
the liver SAF and LIN FA profiles became very close to that of the Lard diet. Nevertheless,
the n-6/n-3 FA ratio in liver LIN remained slightly lower than Lard and SAF.
Page 10 of 41Diabetes
Tissue EC levels
Switching n-6/n-3 FA ratio from 53 to 1 in the diet (SAF vs LIN) affected both AEA
and 2-AG tissue levels in the liver (Figure 2). Comparing SAF vs Lard group aimed to reflect
the impact of a specific elevation of LA on tissue EC contents. Elevating dietary LA increased
only 2-AG in the liver. Likewise, the specific impact of the elevation of n-3 FA in the diet on
EC levels was estimated by comparing LIN to Lard group. In these conditions, AEA was
significantly lower in the liver of LIN mice compared with Lard while the same trend was
observed for 2-AG. In other tested tissues (supplemental figure 1), huge nutritional alteration
of n-6/n-3 FA ratio in the diet always significantly reduced AEA levels except for visceral
adipose tissue (VAT). 2-AG was concomitantly reduced in brain and muscle but not modified
in subcutaneous adipose tissue (SCAT) nor VAT.
Whatever the early diet administered, feeding the HFD raised liver AEA and 2-AG
levels (Figure 2). However, the increase was not significant for 2-AG in SAF series since
levels were already elevated at the end of the LFD. EC levels were also generally increased
after the HFD in brain, VAT and muscle. Otherwise, SCAT appeared to be differently
influenced by the HFD regardless of the early diet as suggested by the decrease in EC levels
(supplemental figure 1).
Transcriptomic and proteomic analysis of ECS (Figure 3A-C)
Data concerning FAAH and MAGL, which mainly hydrolyze AEA and 2-AG
respectively, indicated that the liver protein levels and activity of MAGL were more
influenced by the composition of the early diet than FAAH. In particular, both MAGL protein
levels and activity were reduced by SAF compared to other diets in accordance with higher
levels of 2-AG in this group. Protein levels of NAPE-PLD, which is involved in the formation
Page 11 of 41 Diabetes
of AEA, were also reduced by SAF and LIN compared to Lard diet. Regarding CB1R, liver
mRNA levels were unchanged whatever the diet.
Challenging mice with 30% lard diet induced more pronounced alteration of liver
enzymes linked to ECS. Data related to FAAH indicated a strong downregulation while
NAPE-PLD was increased suggesting an inverse regulation of EC degradation and
biosynthetic pathways in favor of an elevation of AEA levels. HFD concomitantly induced
the mRNA expression of CB1R in the liver for all groups. Interestingly, the impact of the
HFD sometimes appeared to depend on the nutritional history. In particular, CB1R mRNA
expression was lower in the LIN compared to SAF group and FAAH protein levels were
higher in the LIN than in Lard group.
Body composition, plasma parameters and glycemic control
Body weight and fat pad relative mass measured at the end of the early LFD did not
differ among the three groups (Table 2). Nevertheless, LIN induced a significant decrease in
total fat mass as determined by echoMRI. The particular sensitivity of the liver to the different
early diets was indicated by the decrease in relative mass and lipid content induced by SAF
and LIN compared to Lard. Similarly, muscle lipids were also the highest for the Lard group
(data not shown). As expected, total body fat, fat pad weight and tissue lipids were increased
after the HFD challenge but no differences were observed between groups.
Early feeding with SAF and LIN experimental diets improved some important plasma
parameters related to glucose and lipid homeostasis in comparison with Lard (Table 2).
Notably, fasting triglyceridemia and cholesterolemia were reduced after SAF and LIN diets.
While these diets did not affect glycemia, insulin levels in these groups were higher than in
Lard suggesting a possible impairment of beta-cell function by early and prolonged exposure
to Lard diet. Interestingly, plasma adiponectin was significantly higher in LIN than in Lard
Page 12 of 41Diabetes
pointing out a putative impact of n-3 FA on adipose tissue metabolism. Data relative to
glycemic control (Figure 4A and B) showed that only the LIN diet exerted slight changes on
glucose clearance after oral glucose load or insulin administration.
As expected, HFD challenge induced marked variations in most of the metabolic
parameters measured (Table 2). Glycemia, cholesterolemia, insulinemia, adiponectin and
leptin increased in all groups. The slight hyperglycemia associated to the compensatory
hyperinsulinemia reflected the onset of an insulin resistant state whatever the early diet
consumed. However calculations derived from OGTT and insulin response (DI0-15/DG0-15 and
DI0 ) suggested an alteration in beta-cell function for mice fed with the Lard diet only (Table
2). Data also revealed that animals fed with the diet enriched in n-3 FA during 10 weeks
following weaning had higher plasma adiponectin levels and better glycemic control after
HFD challenge. Notably, OGTT, ITT and HOMA-IR were improved in the LIN group
compared to the others (Figure 4C and D and Table 2). In addition, t0-30min insulin production
in response to glucose load was also significantly higher in LIN than Lard (Figure 4E).
Expression of genes related to carbohydrate and lipid metabolism in the liver (Figure 5)
The fact that early feeding with LIN induced long-lasting positive effects on glycemic
control prompted us to study the impact of the different diets on the expression of genes
related to carbohydrate and lipid metabolism in the liver. Thus, early feeding with the LIN
diet significantly decreased mRNA levels of the key gluconeogenic enzymes genes PEPCK
and G6P as well as that of GK, FAS, SCD1 and the transcription factor CREBH compared
with the Lard group. Data also revealed that young mice fed with the diet containing
exclusively lard as lipid source showed the highest mRNA expression of FAT/CD36 and LPL
genes related to FA uptake. This observation also applied to TNFα mRNA levels suggesting
Page 13 of 41 Diabetes
an elevated liver inflammatory status in Lard mice liver which was decreased by the SAF and
LIN diets.
Whatever the early diet, feeding mice with HFD induced changes in the expression of
genes responsive to insulin such as PEPCK and GK, which were respectively decreased and
increased. We further noticed that mice prefed with the LIN diet showed lower expression of
several genes after HFD challenge compared with other diets suggesting that addition of n-3
FA in the early diet may induce biological imprinting mechanisms controlling gene
expression. In this way, PEPCK, CREBH, LPL, and TNFα mRNA levels were lower in LIN
than SAF and Lard groups.
EC levels and gene expression in Fat-1 mice liver (Figure 6)
For further insight on the impact of n-3 FA tissue enrichment on ECS tone, we measured EC
content in the liver of Fat-1 mice. These transgenic animals are able to endogenously
synthesize n-3 FA from n-6 FA and consequently exhibit high levels of n-3 FA in their
tissues. Interestingly, EC levels were strongly reduced in Fat-1 mouse livers (Figure 6A). We
also found that the expression of FAAH, PEPCK, G6P and FAS gene was lower in Fat-1 than
in wild type mice (Figure 6B).
DISCUSSION
The objective of this study was twofold. First, we explored whether early exposure to
a diet enriched in n-3 or n-6 FA could concomitantly influence EC tone in several mouse
tissues and metabolic parameters with particular attention to the liver, considered the most
vulnerable organ following nutritional programming during perinatal period. Secondly, we
examined the long-term effects of these postnatal nutritional manipulations by examining
Page 14 of 41Diabetes
whether they were associated with alterations of metabolic parameters in response to a later
HFD challenge. Our data indicate in particular that exposure to an n-3 FA-enriched diet in the
early age induces a marked reduction in liver ECS activity associated with an alteration of key
enzymes involved in liver carbohydrate and lipid metabolism. In addition, we observed that
some of the liver gene expression modifications induced by n-3 FA feeding in the first weeks
of life persisted after HFD challenge and were associated with an improved glycemic control.
A recent series of studies carried out by Alvheim et al. highlighted the importance of
the dietary LA on EC tone (11; 12; 14). These works demonstrated that excessive LA
consumption elevates tissue EC levels and is associated with metabolic alterations. Here,
some important issues concerning the impact of dietary FA, and particularly n-3 FA, on ECS
activity were also emphasized. First, we observed that the substitution of 0.5% Lard for LIN
in the early diet was sufficient to decrease EC levels in brain, liver and muscle. Since EC
tissue levels were generally decreased when the diet was enriched in α-LNA regardless of
changes in LA levels, it might be suggested that EC synthesis is more influenced by n-3 than
n-6 dietary FA. The fact that increasing LA in the diet while α-LNA levels remained constant
did not induce marked variation in EC levels also supports this assumption. In line with this,
the decrease in liver AEA induced by chronic administration of LIN compared to Lard could
not be due to a net decrease in the supply of n-6 biosynthetic precursors of EC since LA levels
were in the same range in the two diets. Instead, competition between n-6 and n-3 FA for
elongation and desaturation steps may be crucial for EC synthesis in these conditions. We
also found here that early dietary n-3 FA reduces EC levels in the brain and the skeletal
muscle. Decreases in both AEA and 2-AG, with the former persisting after HFD challenge,
were observed in the LIN compared to SAF group. In the whole, these findings, in agreement
with previous data in adult mice (35) and rats (34) (36), confirm that early dietary
interventions based on n-3 FA, might constitute an alternative strategy to “global” CB1R
Page 15 of 41 Diabetes
blockers to reduce ECS overactivity, and subsequently, various parameters of the metabolic
syndrome, while possibly limiting the consequences on brain function.
Animals from the Lard series were fed with a 5% lipid diet consisting mainly of long
chain saturated and monounsaturated FA initially prone to induce metabolic disorders related
to insulin resistance. So it was not surprising to observe that replacing part of the Lard with
SAF or LIN in the diet was able to limit the alterations of some metabolic parameters such as
triglyceridemia, cholesterolemia, and liver and muscle lipid content in agreement with
previous studies (37). The lower insulin levels observed in Lard compared to SAF and LIN
mice may also represent an impairment of beta-cell function induced by prolonged exposure
to saturated FA (38). However, a notable finding from this work is that only the diet enriched
with α-LNA induced specific changes in the liver expression of genes involved in
gluconeogenesis and de novo lipogenesis. Thus, LIN diet decreased PEPCK, G6P and GK
mRNA levels suggesting a slowing down of liver glucose production. Molecular data also
indicated that dietary n-3 FA reduce the liver expression of SCD1 and FAS suggesting a
decrease in FA de novo synthesis further illustrated by the lower liver lipid content observed
in this group. These findings concur with other studies showing an inhibitory effect of n-3 FA
on gluconeogenesis and de novo lipogenesis (39; 40) two key actors of insulin resistance
setup. Although the changes were not statistically significant, the LIN diet also tended to
improve glucose and insulin tolerance compared to the Lard diet suggesting that possibly
stronger positive effects of the diet might have occurred with a longer treatment.
Our findings are reminiscent of those observed in Fat-1 transgenic mice, which can
endogenously synthesize n-3 FA from n-6 FA and consequently show elevated levels of DHA
in the liver compared to wild type mice. They also appear to be protected from HFD-induced
glucose intolerance, dyslipidemia and liver steatosis (10; 41). A recent study indicated that
Fat-1 mice display reduced capacity for gluconeogenesis and lipid synthesis as suggested by
Page 16 of 41Diabetes
the low hepatic protein expression of PEPCK, G6P, ACC and FAS in the liver (28).
Interestingly, whilst confirming lower mRNA levels of these enzymes, we demonstrated that
AEA and 2-AG levels are also strongly reduced in the liver of Fat-1 mice.
The observation that tissue enrichment with n-3 FA (by dietary or transgenic
manipulation) induces a significant decrease in ECS tone in the liver and muscle supports the
possible existence of a direct causal link between the decrease in EC tone induced by LIN diet
and the improvement of metabolic parameters observed in our study. The role of the ECS in
regulating glucose homeostasis is well known (19; 42-44). In particular, studies using liver-
specific CB1R knockout mice demonstrated that hepatic CB1R activation is both necessary
and sufficient to account for diet-induced hepatic insulin resistance (42). In primary
hepatocytes, direct CB1R activation was found to induce glucose production by increasing
expression of CREBH and gluconeogenic genes (19). CREBH is a liver-specific transcription
factor recently described as a crucial actor in the regulation of hepatic glucose metabolism in
mammals. CREBH has been shown to be induced by fasting or insulin-resistant state in
rodents and to activate transcription of PEPCK or G6Pase gene. Consistent with this, we
observed that mice fed with the LIN diet show low levels of PEPCK, G6P and CREBH
associated with a reduced activity of the ECS in the liver. Therefore, it is conceivable that the
low gluconeogenic gene expression observed in the liver of these mice is mediated by reduced
CREBH expression observed in response to the decrease in EC tone induced by n-3 FA
exposure.
Liu et al. (45) have recently proposed a functional link between the ECS and de novo
lipogenesis pathways that could also apply to our findings. The authors identified hepatic
MUFA generated via SCD1 as endogenous inhibitors of FAAH in the liver and thereby
responsible for elevated hepatic levels of AEA. Here, addition of LIN in the diet increased n-3
FA of liver lipids without depressing n-6 FA but decreased the C18:1/C18:0 ratio, suggesting
Page 17 of 41 Diabetes
that part of the effects might be due to desaturase activity modification. Thus, the low AEA
levels observed in the liver of LIN mice could result from downregulation of FAS and SCD1
gene expression and by a low liver monounsaturated FA production, which in turn would
increase the degradation of AEA by FAAH. The increase in ECS activity induced by HFD
challenge is also in agreement with the potential impact of monounsaturated FA on EC
biosynthesis. Thus, chronic administration of the lipogenic diet might have increased NAPE-
PLD, and decreased FAAH activity, thus leading to higher AEA levels.
Altogether, our results suggest that decreasing ECS activity by introducing n-3 FA in the
early diet induces liver gene expression changes that may contribute to carbohydrate and lipid
metabolism improvements. The reduction in fat mass expansion observed in LIN mice also
suggests a general amelioration of energy homeostasis.
It is widely accepted that the nutritional environment and weight gain in the first years
of life are associated with the risk of developing metabolic disorders. It has been shown that
during the postnatal period, a metabolic imprinting may occur and predispose to an early
onset and aggravation of metabolic disorders induced by exposure to HFD later in life (46). In
the current study, the impact of early diets on the susceptibility to develop metabolic disorders
induced by a subsequent HFD was tested challenging mice with a 30% lard-based diet for 10
weeks. Evidence has accumulated indicating a tonic overactivation of ECS following HFD-
induced obesity (14; 35; 47). Nevertheless, data from the literature also suggest that the effect
of HFD feeding on peripheral EC levels may depend on the FA composition of the diet (12;
14; 48). In the present study, we consistently observed that tissue EC contents were generally
higher after chronic administration of the HFD, whatever the early LFD. Liver transcriptomic
and proteomic analyses related to the ECS also supported a stimulatory effect of HFD on EC
tone as indicated by the marked increase in NAPE-PLD and CB1R expression along with the
Page 18 of 41Diabetes
concomitant decrease in FAAH expression and activity. However an important finding
concerns EC levels in the inguinal AT, which were lowered in all groups after HFD challenge
in agreement with previous works concerning the impact of HFD on adipose depots of both
rodents and humans (47; 49). Since leptin and insulin were strongly increased after HFD
challenge, it might be suggested that the decrease in SCAT EC levels is due to the action of
these hormones on EC production as previously shown (50; 51). This possibility implies that
our dietary conditions did not yet alter SCAT metabolism to such a degree that it became
resistant to hormonal control. The fact that adiponectin levels were increased by HFD
suggests that fat depots still had the capacity to expand by recruiting new adipocytes. Indeed,
adiponectin production is suppressed as adipocytes become hypertrophic and macrophages
infiltrate the tissue (52). So, it would be informative to determine whether ECS activity is still
decreased in other more severe models of obesity in which the SCAT shows excessive
hypertrophy and metabolic stress.
Feeding mice with 30% lard caused the typical metabolic disorders due to diet-induced
obesity independently on the postnatal nutritional history. However the metabolic
consequences were somehow limited likely due to the total lipid content and the duration of
the diet, which were not elevated. Thus, mice became fatter, showed liver triglyceride
accumulation, hyperinsulinemia, hyperleptinemia, slight hyperglycemia and
hypercholesterolemia. While the differences concerning liver EC tone and lipid composition
induced by the LIN early diet did not persist after HFD challenge, we interestingly observed a
better glucose tolerance in these animals compared with the Lard and SAF groups. Data
further suggest that the better glycemic control observed in mice fed with the early LIN diet
was not dependent on beta cell function but rather associated with an improvement of insulin
sensitivity. This may be closely related to the reduced expression of some key genes involved
in lipid and carbohydrate homeostasis in the liver of LIN fed mice. Although differences were
Page 19 of 41 Diabetes
not always quite statistically significant for genes taken individually, the concomitant
decrease in CB1R, PEPCK, G6P, CREBH, FAS, SCD1, SREBP1c, FAT/CD36, LPL and
TNFα mRNA levels collectively suggests the existence of a metabolic imprinting set up by
the early n-3 FA exposure period.
In conclusion our results strongly support the possibility that early dietary n-3 FA
induce a decrease in liver EC tone giving rise to modifications persisting later in life and
promoting resistance towards metabolic complications induced by an obesogenic diet. These
findings support the emerging notion that dietary n-3 FA could be an alternative strategy to
drug use to reduce overactivity of peripheral ECS, and consequently improve or prevent
metabolic disorders related to obesity.
Acknowledgments. The authors thank Serge Monier (Plateforme de Cytométrie) from
INSERM LNC UMR866 for excellent technical assistance.
Funding. This work was supported by funds from the Regional Council of Burgundy and
Groupe Lipides et Nutrition (GLN).
Duality of Interest. No potential conflicts of interest relevant to this article were reported.
Author Contributions. L.D., V.D. and P.D. designed, analyzed the experiments and wrote
the manuscript. L.D., S.T.-F., J.G., T.M and P.D. performed experiments related to fatty acid
compositions, metabolic and molecular parameters. F.P., S.B., and C.S. determined tissue
endocannabinoid contents. F.A.I performed western blotting and enzyme activity
experiments. S.T.-F. reviewed the written draft of the manuscript. J.B. produced Fat-1 mouse
tissue samples. V.D. and P.D. are the guarantors of this work and, as such, had full access to
Page 20 of 41Diabetes
all the data in the study and take responsibility for the integrity of the data and the accuracy of
the data analysis.
REFERENCES
1. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter
RD, Sugiura T, Kunos G: Leptin-regulated endocannabinoids are involved in maintaining
food intake. Nature 2001;410:822-825
2. Quarta C, Mazza R, Obici S, Pasquali R, Pagotto U: Energy balance regulation by
endocannabinoids at central and peripheral levels. Trends Mol Med 2011;17:518-526
3. Williams CM, Kirkham TC: Anandamide induces overeating: mediation by central
cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999;143:315-317
4. Mallat A, Lotersztajn S: Endocannabinoids and their role in fatty liver disease. Dig Dis
2010;28:261-266
5. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, Mukhopadhyay P, Horiguchi N,
Harvey-White J, Marsicano G, Lutz B, Gao B, Kunos G: Paracrine activation of hepatic
CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.
Cell Metab 2008;7:227-235
6. Jourdan T, Demizieux L, Gresti J, Djaouti L, Gaba L, Verges B, Degrace P: Antagonism of
peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice:
evidence from cultured explants. Hepatology 2012;55:790-799
7. Buggy Y, Cornelius V, Wilton L, Shakir SA: Risk of depressive episodes with rimonabant:
a before and after modified prescription event monitoring study conducted in England.
Drug Saf 2011;34:501-509
8. Di Marzo V, Despres JP: CB1 antagonists for obesity--what lessons have we learned from
rimonabant? Nat Rev Endocrinol 2009;5:633-638
9. Di Marzo V: Endocannabinoids: synthesis and degradation. Rev Physiol Biochem
Pharmacol 2008;160:1-24
10. Li J, Li FR, Wei D, Jia W, Kang JX, Stefanovic-Racic M, Dai Y, Zhao AZ: Endogenous
omega-3 polyunsaturated fatty acid production confers resistance to obesity,
dyslipidemia, and diabetes in mice. Mol Endocrinol 2014;28:1316-1328
Page 21 of 41 Diabetes
11. Alvheim AR, Torstensen BE, Lin YH, Lillefosse HH, Lock EJ, Madsen L, Froyland L,
Hibbeln JR, Malde MK: Dietary linoleic acid elevates the endocannabinoids 2-AG and
anandamide and promotes weight gain in mice fed a low fat diet. Lipids 2014;49:59-69
12. Alvheim AR, Torstensen BE, Lin YH, Lillefosse HH, Lock EJ, Madsen L, Hibbeln JR,
Malde MK: Dietary linoleic acid elevates endogenous 2-arachidonoylglycerol and
anandamide in Atlantic salmon (Salmo salar L.) and mice, and induces weight gain and
inflammation in mice. Br J Nutr 2013;109:1508-1517
13. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V: Anandamide and diet:
inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of
the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A
2001;98:6402-6406
14. Alvheim AR, Malde MK, Osei-Hyiaman D, Lin YH, Pawlosky RJ, Madsen L, Kristiansen
K, Froyland L, Hibbeln JR: Dietary linoleic acid elevates endogenous 2-AG and
anandamide and induces obesity. Obesity (Silver Spring) 2012;20:1984-1994
15. Sato A, Kawano H, Notsu T, Ohta M, Nakakuki M, Mizuguchi K, Itoh M, Suganami T,
Ogawa Y: Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-
induced obesity: importance of hepatic lipogenesis. Diabetes 2010;59:2495-2504
16. Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, Giordano E, Sanna F,
Bisogno T, Uda S, Collu M, Bruheim I, Di Marzo V, Banni S: Endocannabinoids may
mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators
in obese Zucker rats. J Nutr 2009;139:1495-1501
17. Kalupahana NS, Claycombe K, Newman SJ, Stewart T, Siriwardhana N, Matthan N,
Lichtenstein AH, Moustaid-Moussa N: Eicosapentaenoic acid prevents and reverses
insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue
inflammation. J Nutr 2010;140:1915-1922
18. Hein GJ, Chicco A, Lombardo YB: Fish oil normalizes plasma glucose levels and
improves liver carbohydrate metabolism in rats fed a sucrose-rich diet. Lipids
2012;47:141-150
19. Chanda D, Kim DK, Li T, Kim YH, Koo SH, Lee CH, Chiang JY, Choi HS: Cannabinoid
receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of
endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding
protein H (CREBH) in primary hepatocytes. J Biol Chem 2011;286:27971-27979
Page 22 of 41Diabetes
20. Furuya DT, Poletto AC, Freitas HS, Machado UF: Inhibition of cannabinoid CB1 receptor
upregulates Slc2a4 expression via nuclear factor-kappaB and sterol regulatory element-
binding protein-1 in adipocytes. J Mol Endocrinol 2012;49:97-106
21. Zalewski BM, Patro B, Veldhorst M, Kouwenhoven S, Escobar PC, Lerma JC, Koletzko
B, Van Goudoever JB, Szajewska H: Nutrition of Infants and Young Children (1-3
Years) and its Effect on Later Health: A Systematic Review of Current
Recommendations (EarlyNutrition Project). Crit Rev Food Sci Nutr 2015:0
22. Glavas MM, Kirigiti MA, Xiao XQ, Enriori PJ, Fisher SK, Evans AE, Grayson BE,
Cowley MA, Smith MS, Grove KL: Early overnutrition results in early-onset arcuate
leptin resistance and increased sensitivity to high-fat diet. Endocrinology 2010;151:1598-
1610
23. Liu Z, Lim CY, Su MY, Soh SL, Shui G, Wenk MR, Grove KL, Radda GK, Han W, Xiao
X: Neonatal overnutrition in mice exacerbates high-fat diet-induced metabolic
perturbations. J Endocrinol 2013;219:131-143
24. Massiera F, Barbry P, Guesnet P, Joly A, Luquet S, Moreilhon-Brest C, Mohsen-Kanson
T, Amri EZ, Ailhaud G: A Western-like fat diet is sufficient to induce a gradual
enhancement in fat mass over generations. J Lipid Res 2010;51:2352-2361
25. Pouteau E, Aprikian O, Grenot C, Reynaud D, Pace-Asciak C, Cuilleron CY, Castaneda-
Gutierrez E, Moulin J, Pescia G, Beysen C, Turner S, Mace K: A low alpha-linolenic
intake during early life increases adiposity in the adult guinea pig. Nutr Metab (Lond)
2010;7:8
26. Massiera F, Saint-Marc P, Seydoux J, Murata T, Kobayashi T, Narumiya S, Guesnet P,
Amri EZ, Negrel R, Ailhaud G: Arachidonic acid and prostacyclin signaling promote
adipose tissue development: a human health concern? J Lipid Res 2003;44:271-279
27. Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, Titos E,
Martinez-Clemente M, Lopez-Parra M, Arroyo V, Claria J: Obesity-induced insulin
resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins
and protectins. FASEB J 2009;23:1946-1957
28. Romanatto T, Fiamoncini J, Wang B, Curi R, Kang JX: Elevated tissue omega-3 fatty acid
status prevents age-related glucose intolerance in fat-1 transgenic mice. Biochim Biophys
Acta 2014;1842:186-191
29. Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A, Rialland M, Tessier C,
Kang JX, Narce M: High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1
mice: inflammatory pathway inhibition. Diabetes 2011;60:1090-1099
Page 23 of 41 Diabetes
30. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification
of total lipides from animal tissues. J Biol Chem 1957;226:497-509
31. Christie WW: A simple procedure for rapid transmethylation of glycerolipids and
cholesteryl esters. J Lipid Res 1982;23:1072-1075
32. Niot I, Gresti J, Boichot J, Sempore G, Durand G, Bezard J, Clouet P: Effect of dietary n-
3 and n-6 polyunsaturated fatty acids on lipid-metabolizing enzymes in obese rat liver.
Lipids 1994;29:481-489
33. Bartelt A, Orlando P, Mele C, Ligresti A, Toedter K, Scheja L, Heeren J, Di Marzo V:
Altered endocannabinoid signalling after a high-fat diet in Apoe(-/-) mice: relevance to
adipose tissue inflammation, hepatic steatosis and insulin resistance. Diabetologia
2011;54:2900-2910
34. Iannotti FA, Piscitelli F, Martella A, Mazzarella E, Allara M, Palmieri V, Parrella C,
Capasso R, Di Marzo V: Analysis of the "endocannabinoidome" in peripheral tissues of
obese Zucker rats. Prostaglandins Leukot Essent Fatty Acids 2013;89:127-135
35. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V: Dysregulation of
peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets.
Mol Cell Endocrinol 2008;286:S66-78
36. Di Marzo V, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, Giordano E, Bisogno
T, Collu M, Batetta B, Uda S, Berge K, Banni S: Dietary krill oil increases
docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine
levels in the brain of obese Zucker rats. Int Dairy J 2010;20:231-235
37. Sealls W, Gonzalez M, Brosnan MJ, Black PN, DiRusso CC: Dietary polyunsaturated
fatty acids (C18:2 omega6 and C18:3 omega3) do not suppress hepatic lipogenesis.
Biochim Biophys Acta 2008;1781:406-414
38. Elks ML: Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated
insulin release. Endocrinology 1993;133:208-214
39. Delarue J, LeFoll C, Corporeau C, Lucas D: N-3 long chain polyunsaturated fatty acids: a
nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?
Reprod Nutr Dev 2004;44:289-299
40. Rossi AS, Lombardo YB, Chicco AG: Lipogenic enzyme activities and glucose uptake in
fat tissue of dyslipemic, insulin-resistant rats: effects of fish oil. Nutrition 2010;26:209-
217
41. White PJ, Arita M, Taguchi R, Kang JX, Marette A: Transgenic restoration of long-chain
n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates
Page 24 of 41Diabetes
obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes
2010;59:3066-3073
42. Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J, Yin S, Gao P, Shan X,
Pickel J, Bataller R, O'Hare J, Scherer T, Buettner C, Kunos G: Hepatic cannabinoid
receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and
clearance in mice. Gastroenterology 2012;142:1218-1228 e1211
43. Silvestri C, Di Marzo V: The endocannabinoid system in energy homeostasis and the
etiopathology of metabolic disorders. Cell Metab 2013;17:475-490
44. Troy-Fioramonti S, Demizieux L, Gresti J, Muller T, Verges B, Degrace P: Acute
activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and
improves postprandial glycemia in mice. Diabetes 2015;64:808-818
45. Liu J, Cinar R, Xiong K, Godlewski G, Jourdan T, Lin Y, Ntambi JM, Kunos G:
Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous
inhibitors of fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2013;110:18832-
18837
46. Sullivan EL, Grove KL: Metabolic imprinting in obesity. Forum Nutr 2010;63:186-194
47. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, Di Marzo V:
Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a
high-fat diet. Obesity (Silver Spring) 2008;16:553-565
48. Piscitelli F, Carta G, Bisogno T, Murru E, Cordeddu L, Berge K, Tandy S, Cohn JS,
Griinari M, Banni S, Di Marzo V: Effect of dietary krill oil supplementation on the
endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr
Metab (Lond) 2011;8:51
49. Annuzzi G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G, Bozzetto L, Riccardi
G, Verde R, Petrosino S, Rivellese AA, Di Marzo V: Differential alterations of the
concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue
of obese diabetic patients. Lipids Health Dis 2010;9:43
50. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S,
Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V:
Regulation, function, and dysregulation of endocannabinoids in models of adipose and
beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab
2006;91:3171-3180
Page 25 of 41 Diabetes
51. D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR: The role of adipocyte
insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids.
Diabetes 2008;57:1262-1268
52. Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and
adipokine expression and secretion. J Clin Endocrinol Metab 2007;92:1023-1033
FIGURE LEGEND
Figure 1. Schematic illustration of (A) the pathways for biosynthesis and degradation of
endocannabinoids and (B) the experimental study design.
AEA : N-arachidonoyl-ethanolamine ; 2-AG : 2-arachidonoyl-glycerol ; ECs :
Endocannabinoids ; FAAH : Fatty acid amide hydrolase ; MAGL : Monoacylglycerol lipase ;
NAPE-PLD : N-acylphosphatidylethanolamine phospholipase D.
Figure 2. Effect of early diets and later high-fat diet challenge on liver N-arachidonoyl-
ethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG) contents. Three-week old mice
were fed a 5% lipid diet containing either lard or lard + safflower oil (SAF) or lard + linseed
oil (LIN) for 10 weeks (early LF diet). Then mice were all challenged with a 30% lard diet for
10 additional weeks (HF diet challenge). Results are expressed as means ± SEM (n=4-6). Two
different superscript letters indicate significant statistical differences between groups after
early LF diet or after HF diet challenge at p<0.05. *Asterisks indicate significant statistical
differences between HF diet challenge vs corresponding early LF diet means (p<0.05).
Figure 3. Effect of early diets and later high-fat diet challenge on regulation of proteins
involved in liver endocannabinoid system activity. Three-week old mice were fed a 5% lipid
diet containing either lard or lard + safflower oil (SAF) or lard + linseed oil (LIN) for 10
Page 26 of 41Diabetes
weeks (early LF diet). Then mice were all challenged with a 30% lard diet for 10 additional
weeks (HF diet challenge). (A) Gene expression analysis of CB1R, NAPE-PLD (denoted as
NAPE) and FAAH. (B). Representative immunoblots of liver protein analysis of FAAH,
NAPE-PLD (denoted as NAPE) and MAGL with graphical densitometry quantification. (C)
FAAH and MAGL activity measured in 4 separated samples as described in Materials and
Methods. Results are expressed as means ± SEM (n=4-6). Two different superscript letters
indicate significant statistical differences between groups after early LF diet or after HF diet
challenge at p<0.05. *Asterisks indicate significant statistical differences between HF diet
challenge vs corresponding early LF diet means (p<0.05).
Figure 4. Effect of early diets and later high-fat diet challenge on glycemic control. Three-
week old mice were fed a 5% lipid diet containing either lard or lard + safflower oil (SAF) or
lard + linseed oil (LIN) for 10 weeks (early LF diet) and subject to (A) oral glucose tolerance
test (OGTT, 2 g/kg) and (B) insulin tolerance test (ITT, 0.5 UI/kg). Then mice were all
challenged with a 30% lard diet for 10 additional weeks (HF diet challenge) and subject to
(C) OGTT and (D) ITT. (E) Plasma insulin appearance after oral glucose load (2 g/kg) was
determined after HF diet challenge. Results are expressed as means ± SEM (n=7-9).
* p<0.05, LIN vs Lard and SAF.† p<0.05, LIN vs SAF. $ p<0.05, LIN vs Lard
Figure 5. Expression of genes related to carbohydrate and lipid metabolism in the liver.
Three-week old mice were fed a 5% lipid diet containing either lard or lard + safflower oil
(SAF) or lard + linseed oil (LIN) for 10 weeks (early LF diet). Then mice were all challenged
with a 30% lard diet for 10 additional weeks (HF diet challenge). Results are expressed as
means ± SEM (n=6-9). Two different superscript letters indicate significant statistical
differences between groups after early LF diet or after HF diet challenge at p<0.05. *Asterisks
Page 27 of 41 Diabetes
indicate significant statistical differences between HF diet challenge vs corresponding early
LF diet means (p<0.05).
CREBH : Cyclic AMP-response element-binding protein H ; FAS : Fatty acid synthase ;
FAT/CD36 : Fatty acid translocase ; GK : Glucokinase ; G6P : Glucose-6-phosphatase ; LPL :
Lipoprotein lipase ; PEPCK : Phosphoenolpyruvate carboxykinase ; SCD1 : Stearoyl-CoA
desaturase 1; TNF-α : Tumor necrosis factor α.
Figure 6. N-arachidonoyl-ethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG) contents
and expression of genes related to the ECS and carbohydrate and lipid metabolism in the liver
of Fat-1 mice. (A) Liver AEA and 2-AG contents. (B) Gene expression analysis. Results are
expressed as means ± SEM (n=5). *Asterisks indicate significant statistical differences
between groups at p<0.05.
FAS : Fatty acid synthase ; GK : Glucokinase ; G6P : Glucose-6-phosphatase ; PEPCK :
Phosphoenolpyruvate carboxykinase.
Sup Figure 1. N-arachidonoyl-ethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG)
levels in (A) Brain, (B) muscle, (C) visceral adipose tissue (VAT) and (D) subcutaneous
adipose tissue (SCAT) (B). Three-week old mice were fed a 5% lipid diet containing either
lard or lard + safflower oil (SAF) or lard + linseed oil (LIN) for 10 weeks (early LF diet).
Then mice were all challenged with a 30% lard diet for 10 additional weeks (HF diet
challenge). Results are expressed as means ± SEM (n=3-6). Two different superscript letters
indicate significant statistical differences between groups after early LF diet or after HF diet
challenge at p<0.05. *Asterisks indicate significant statistical differences between HF diet
challenge vs corresponding early LF diet means (p<0.05).
Page 28 of 41Diabetes
Page 29 of 41 Diabetes
Table 1. Diet and liver total fatty acid composition
FA
Diet
Liver
after early LF diet
Liver
after HF diet challenge
(% total FA) Lard SAF LIN Lard SAF LIN Lard SAF LIN
C14 :0
2.1
1.2
1.7
- - - - - -
C16:0
27.7
17.6
24.0
24.40
± 0.56
22.49
± 0.24
25.36
± 0.22
25.19*
± 0.25
25.34*
± 0.36
26.23*
± 0.35
C16:1n-7
3.1
1.7
2.6
7.69a
± 1.14
4.00b
± 0.21
7.29a
± 0.28
4.38*
± 0.14
4.14
± 0.12
4.26*
± 0.16
C18:0
16.7
9.1
14.4
3.71a
± 0.19
7.97b
± 0.54
4.83a
± 0.17
3.91
± 0.44
3.82*
± 0.43
3.92*
± 0.43
C18:1n-9
40.5
28.1
37.4
44.47a
± 0.19
22.75b
± 0.81
35.63c
± 0.67
47.75*
± 1.63
46.49*
± 1.65
45.58*
± 1.73
C18:2n-6
8.6
40.9
10.0
5.11a
± 0.09
18.0b
± 0.51
7.34c
± 0.18
5.92*
± 0.33
6.33*
± 0.44
6.68
± 0.37
C18:3n-3
0.4
0.8
9.2
- - - - - -
C20:4n-6
- - - 5.49a
± 0.36
14.0b
± 0.80
3.94c
± 0.09
5.23*
± 0.82
5.09*
± 0.83
5.05*
± 0.79
C22:6n-3
- - - 1.14a
± 0.17
2.34b
± 0.09
7.25c
± 0.13
0.27a*
± 0.22
1.37b*
± 0.22
1.99b*
± 0.40
n-6/n-3
22.3 52.7 1.1 8.72a
± 0.10
13.46b
± 0.73
1.03c
± 0.02
8.73a
± 0.63
9.34a*
± 0.59
6.36b*
± 0.50
Liver fatty acids (FA) are expressed as means ± SEM (n=7-9). Two different superscript letters indicate significant statistical differences between groups after early LF diet or after HF diet challenge at p<0.05. Values are not indicated when fatty acid content did not reach 1g/100g in at least one series. *Asterisks indicate significant statistical differences between HF diet challenge vs corresponding early LF diet means (p<0.05).
Page 30 of 41Diabetes
Table 2. Body composition and plasma parameters.
After early LF diet After HF diet challenge
Lard SAF LIN Lard SAF LIN n=7 n=7 n=7 n=7 n=9 n=7
Body weight (g)
22.7
± 0.74
22.8
± 0.47
23.5
± 0.74
35.4*
± 1.60
36.3*
± 2.13
36.4*
± 1.63
Liver
(% of bw)
4.43a
± 0.07
3.61b
± 0.10
3.61b
± 0.07
4.00
± 0.19
4.17
± 0.25
3.78
± 0.22
pVAT
(% of bw)
2.19
± 0.17
2.23
± 0.08
2.34
± 0.17
6.19
± 0.34
5.91
± 0.42
6.33
± 0.29
iSCAT
(% of bw)
1.33a
± 0.07
1.02b
± 0.04
1.16c
± 0.06
2.74
± 0.28
2.84
± 0.31
2.82
± 0.18
Fat mass
(% of bw)
13.9 a
± 0.46
14.8 a
± 0.95
12.9 b
± 0.27
33.3*
± 1.73
33.4*
± 2.43
34.3*
± 1.88
Triglycerides
(mg/ml)
0.43a
± 0.04
0.27b
± 0.03
0.29b
± 0.04
0.27*
± 0.02
0.32
± 0.03
0.28
± 0.02
Cholesterol
(mg/ml)
1.30a
± 0.06
1.17b
± 0.09
1.07b
± 0.12
1.68*
± 0.12
1.71*
± 0.12
1.69*
± 0.05
Adiponectin
(µg/ml)
15.5a
± 2.17
20.9b
± 3.07
22.3b
± 2.59
28.66a*
± 1.69
31.75ab*
± 1.61
35.54b*
± 2.16
Leptin
(pg/ml)
40.1
± 26.6
16.1
± 10.5
21.0
± 10.1
526.4*
± 129.1
890.5*
± 156.1
622.6*
± 141.3
Insulin
(pg/ml)
25.4a
± 15.4
108.3b
± 36.0
131.5b
± 62.7
715.5*
± 168.3
837.0*
± 151.5
755.9*
± 119.2
Glucose
(g/l)
1.76
± 0.06
1.70
± 0.02
1.63
± 0.10
2.07*
± 0.14
2.09*
± 0.11
1.97*
± 0.08
HOMA-IR - - - 20.0ab
± 2.63
22.7a
± 3.40
15.4bc
± 1.98
DI0-15/DG0-15 - - - -176a
±220
2344b
±646
1993b
±504
Page 31 of 41 Diabetes
DI0 - - - -0.002a
±0.005
0.056b
±0.014
0.060b
±0.013
All parameters except glucose levels were measured from blood and tissue samples collected the day of sacrifice on overnight-fasted animals. Glucose levels and calculations were determined from blood samples collected during OGTT experiments initiated with 6h-fasting animals. HOMA-IR = fasting glucose (mmol/l)*fasting insulin(µUI/l)/22.5. DI0-15/DG0-15 : insulin production to glucose load (µUI/mmol). DI0 : Oral disposition index (mmol-1) = (DI0-15/DG0-15)*1/fasting insulin Results are expressed as means ± SEM (n=7-9). Two different superscript letters indicate significant statistical differences between groups after early LF diet or after HF diet challenge at p<0.05. *Asterisks indicate significant statistical differences between HF diet challenge vs corresponding early LF diet means (p<0.05).
Page 32 of 41Diabetes
Figure 1
382x551mm (300 x 300 DPI)
Page 33 of 41 Diabetes
Figure 2
382x551mm (300 x 300 DPI)
Page 34 of 41Diabetes
Figure 3
382x551mm (300 x 300 DPI)
Page 35 of 41 Diabetes
Figure 4
382x551mm (300 x 300 DPI)
Page 36 of 41Diabetes
Figure 5
382x551mm (300 x 300 DPI)
Page 37 of 41 Diabetes
Figure 6
382x551mm (300 x 300 DPI)
Page 38 of 41Diabetes
Supplementary table 1. Primers for real-time PCR
Gene 5'-sense primer-3'
5'-antisense primer-3'
CB1R ccgcaaagatagtcccaatg aaccccacccagtttgaac
CREBH gcacctgcatagcggtccttctg gggatgcagcgtggttgtgga
FAAH ggaccttgctcccctttct cctgctgggctgtcacata
FAS ggctgcagtgaatgaatttg ttcgtacctccttggcaaac
FAT/CD36 aattagtagaaccgggccac ccaactcccaggtacaatca
GK actttccaggccacaaaca tcccagaactgtaagccactc
G6P tggcctggcttattgtacct gtgctaagaggaagacccga
LPL ctaaggacccctgaagacaca tctcatacattcccgttaccgt
NAPE-PLD ctcgatatctgcgtggaaca ctgaattctggcgctttctc
PEPCK cagccagtgccccattatt ccaccaaagatgataccctca
SCD1 ccggagaccccttagatcga tagcctgtaaaagatttctgcaaacc
TNF-a cggggtgatcggtccccaaag tggtttgctacgacgtgggct
18S gtgtggggagtgaatggtg gcgagacagtcaaaccacg
L38 catgcctcggaaaattgag tcttgacagacttggcatcct
TPB acggcacaggacttactcca gctgtctttgttgctcttccaa
Primer pairs were designed using Primers! software or NCBI/ Primer-BLAST and
were synthesized by MWG-Biotech AG (Ebersberg, Germany). CB1R : Cannabinoid
receptor 1 ; CREBH : Cyclic AMP-response element-binding protein H ; FAAH :
Fatty acid amide hydrolase ; FAS : Fatty acid synthase ; FAT/CD36 : Fatty acid
translocase ; GK : Glucokinase ; G6P : Glucose-6-phosphatase ; LPL : Lipoprotein
lipase ; NAPE-PLD : N-acyl phosphatidylethanolamine phospholipase D; PEPCK :
Phosphoenolpyruvate carboxykinase ; SCD1 : Stearoyl-CoA desaturase 1; TNF-α :
Tumor necrosis factor α ; 18S : 18S ribosomal RNA ; L38 : L38 Ribosomal protein;
TPB : TATA box binding protein.
Page 39 of 41 Diabetes
264x382mm (72 x 72 DPI)
Page 40 of 41Diabetes
Sup Figure 1. N-arachidonoyl-ethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG)
levels in (A) Brain, (B) muscle, (C) visceral adipose tissue (VAT) and (D) subcutaneous
adipose tissue (SCAT) (B). Three-week old mice were fed a 5% lipid diet containing either
lard or lard + safflower oil (SAF) or lard + linseed oil (LIN) for 10 weeks (early LF diet).
Then mice were all challenged with a 30% lard diet for 10 additional weeks (HF diet
challenge). Results are expressed as means ± SEM (n=3-6). Two different superscript letters
indicate significant statistical differences between groups after early LF diet or after HF diet
challenge at p<0.05. *Asterisks indicate significant statistical differences between HF diet
challenge vs corresponding early LF diet means (p<0.05).
Page 41 of 41 Diabetes
top related